EGFR ACTIVATING MUTATION
Clinical trials for EGFR ACTIVATING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR ACTIVATING MUTATION trials appear
Sign up with your email to follow new studies for EGFR ACTIVATING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to shrink lung tumors before surgery
Disease control Not yet recruitingThis study tests whether taking two drugs—firmonertinib (a targeted pill) and bevacizumab (an infusion)—for three months before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). After surgery, patients may continue firmonertini…
Matched conditions: EGFR ACTIVATING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 26, 2026 19:13 UTC
-
AI reads scans and genes to predict lung cancer drug success
Knowledge-focused Not yet recruitingThis study uses artificial intelligence to analyze CT scans, pathology slides, and genetic reports from 1,000 lung cancer patients with EGFR mutations. The goal is to build a model that predicts how well targeted therapy will work after surgery. If successful, it could help docto…
Matched conditions: EGFR ACTIVATING MUTATION
Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC